A Phase 3 interventional study of Ertugliflozin and Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-09-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 9th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8,246 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 2nd largest by enrollment of the 170 interventional ones that give a count, is one of 13 that started in 2013, is one of 86 in phase 3, and was the 153rd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An overall study of the cardiovascular outcomes following treatment with ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and established vascular disease. The main objective of this study is to assess the cardiovascular safety of ertugliflozin. This trial includes 3 pre-defined glycemic sub-studies; 1. In participants receiving background insulin with or without metformin, 2. In participants receiving background sulfonylurea monotherapy, and 3. In participants receiving background metformin with sulfonylurea (all fully-enrolled).
Participants enrolled prior to Amendment 1 were in the overall study as well as a sub-study, if they met certain entry criteria. Participants enrolled following the start of Amendment 1 were only enrolled in the overall study. The sub-studies were the initial 18 weeks of the overall study period.
The primary hypotheses for the 4 studies are:
Overall Cardiovascular Study:
The time to first occurrence of the composite endpoint of MACE: cardiovascular death, non-fatal myocardial infarction [MI] or non-fatal stroke in participants treated with ertugliflozin is non-inferior compared to that in participants treated with placebo.
The 3 Glycemic Sub-studies:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (Overall Cardiovascular Study):
Key Inclusion Criteria for the 3 Glycemic Sub-studies:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ertugliflozin 15 mg administered orally once daily for up to approximately 6 years
Drug: Ertugliflozin · Drug: Glycemic Rescue
Ertugliflozin 5 mg administered orally once daily for up to approximately 6 years
Drug: Ertugliflozin · Drug: Placebo · Drug: Glycemic Rescue
Matching placebo to ertugliflozin administered orally once daily for up to approximately 6 years
Drug: Placebo · Drug: Glycemic Rescue
Oral, once daily, for up to approximately 6 years
Also known as: MK-8835, PF-04971729, Steglatro
Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years
Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea \[SU\], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.
Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study)
Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke. The on-treatment approach included confirmed events that occurred between the date of first dose of study medication and the on-treatment censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or 365 days after the last dose).
Time frame: Up to approximately 6 years
Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.
Time frame: Baseline
Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.
Time frame: Baseline
Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects Week 0 A1C.
Time frame: Baseline
Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Time to Occurrence of Cardiovascular (CV) Death or Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)
Time to the occurrence of any of the following adjudicated components of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)) or hospitalization for heart failure. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).
Time frame: Up to approximately 6 years
Time to Occurrence of Cardiovascular Death (On-study Approach) (Overall Cardiovascular Study)
Time to the occurrence of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to CV death or time to censoring (the earliest of participants' end of study date or date last known to be alive).
Time frame: Up to approximately 6 years
Time to First Occurrence of the Renal Composite: the Composite of Renal Death, Renal Dialysis/Transplant, or Doubling of Serum Creatinine From Baseline (On-Study Approach) (Overall Cardiovascular Study)
Renal composite endpoint was defined as a composite of renal death, renal dialysis/transplant, or doubling of serum creatinine from baseline. The on-study approach included events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.
Time frame: Up to approximately 6 years
Time to First Occurrence of MACE Plus (Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke or Hospitalization for Unstable Angina) (On-Study Approach) (Overall Cardiovascular Study)
Time to the first occurrence of any of the following adjudicated components 4-point MACE: cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina pectoris. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.
Time frame: Up to approximately 6 years
Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction (On-Study Approach) (Overall Cardiovascular Study)
Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).
Time frame: Up to approximately 6 years
Time to First Occurrence of Fatal or Non-fatal Stroke (FNF Stroke) (On-Study Approach) (Overall Cardiovascular Study)
Time to the first occurrence of fatal and no-fatal stroke. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.
Time frame: Up to approximately 6 years
Time to First Occurrence of Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)
Time to the first occurrence of heart failure requiring hospitalization (adjudicated). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.
Time frame: Up to approximately 6 years
Time to Occurrence of Death From Any Cause (On-Study Approach) (Overall Cardiovascular Study)
Time to the occurrence of death from any cause. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or date last known to be alive. The on-study approach included events that occurred between the randomization date and the on-study censor date.
Time frame: Up to approximately 6 years
Andersen-Gill Model for Total MACE (On-Study Approach) (Overall Cardiovascular Study)
All events (first and recurrent) of the composite of MACE (3-point major adverse cardiovascular events: cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke) were assessed using Andersen-Gill model. The on-study approach included events that occurred between the randomization date and the on-study censor date.
Time frame: Up to approximately 6 years
Andersen-Gill Model for All Cardiovascular Death (CV Death) or Hospitalizations for Heart Failure (HFF) (On-Study Approach) (Overall Cardiovascular Study)
All events (first and recurrent) of the composite of CV death and HHF were assessed using an Andersen-Gill model. Person-years were calculated as the sum of time from randomization to end of follow-up. The on-study approach included events that occurred between the randomization date and the on-study censor date.
Time frame: Up to approximately 6 years
Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in A1C at Week 52 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Week 52
Change From Baseline in A1C at Month 24 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 24 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 24
Change From Baseline in A1C at Month 36 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 36 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 36
Change From Baseline in A1C at Month 48 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 48 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 48
Change From Baseline in A1C at Month 60 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 60 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 60
Change From Baseline in A1C at Month 72 (Overall Cardiovascular Study)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 72 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 72
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Week 18
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 52 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Week 52
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 24 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Month 24
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 36 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Month 36
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 48 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Month 48
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 60 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Month 60
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Week 18 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Week 18
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Week 52 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Week 52
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 24 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Month 24
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 36 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Month 36
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 48 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Month 48
Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 60 (Overall Cardiovascular Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Month 60
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)
FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding rescue", excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 (Overall Cardiovascular Study)
FPG was analyzed after an overnight fast. This change from baseline reflects the Week 52 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Week 52
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 24 (Overall Cardiovascular Study)
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 24 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 24
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 36 (Overall Cardiovascular Study)
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 36 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 36
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 48 (Overall Cardiovascular Study)
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 48 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 48
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 60 (Overall Cardiovascular Study)
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 60 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 60
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 72 (Overall Cardiovascular Study)
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 72 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 72
Time to the First Occurrence of a Participant Receiving Glycemic Rescue Therapy Through Week 18 (Overall Cardiovascular Study)
Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.
Time frame: Up to 18 weeks
Time to Initiation of Insulin for Participants Not on Insulin at Baseline (Overall Cardiovascular Study)
Participants who were not on insulin therapy at the start of study medication.
Time frame: Up to approximately 6 years
Baseline Insulin Dose for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
Baseline reflects Week 0 insulin dose.
Time frame: Baseline
Change From Baseline in Insulin Dose at Week 18 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.
Time frame: Baseline and Week 18
Change From Baseline in Insulin Dose at Week 52 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
This change from baseline reflects the Week 52 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.
Time frame: Baseline and Week 52
Change From Baseline in Insulin Dose at Month 24 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
This change from baseline reflects the Month 24 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.
Time frame: Baseline and Month 24
Change From Baseline in Insulin Dose at Month 36 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
This change from baseline reflects the Month 36 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.
Time frame: Baseline and Month 36
Change From Baseline in Insulin Dose at Month 48 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
This change from baseline reflects the Month 48 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.
Time frame: Baseline and Month 48
Change From Baseline in Insulin Dose at Month 60 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)
This change from baseline reflects the Month 60 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.
Time frame: Baseline and Month 60
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)
This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding rescue", excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 (Overall Cardiovascular Study)
This change from baseline reflects the Week 52 sitting SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Week 52
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 24 (Overall Cardiovascular Study)
This change from baseline reflects the Month 24 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 24
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 36 (Overall Cardiovascular Study)
This change from baseline reflects the Month 36 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 36
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 48 (Overall Cardiovascular Study)
This change from baseline reflects the Month 48 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 48
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 60 (Overall Cardiovascular Study)
This change from baseline reflects the Month 60 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 60
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 72 (Overall Cardiovascular Study)
This change from baseline reflects the Month 72 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 72
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)
This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding rescue", excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 52 (Overall Cardiovascular Study)
This change from baseline reflects the Week 52 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Week 52
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 24 (Overall Cardiovascular Study)
This change from baseline reflects the Month 24 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 24
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 36 (Overall Cardiovascular Study)
This change from baseline reflects the Month 36 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 36
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 48 (Overall Cardiovascular Study)
This change from baseline reflects the Month 48 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 48
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 60 (Overall Cardiovascular Study)
This change from baseline reflects the Month 60 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 60
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 72 (Overall Cardiovascular Study)
This change from baseline reflects the Month 72 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 72
Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)
This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in Body Weight at Week 52 (Overall Cardiovascular Study)
This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Week 52
Change From Baseline in Body Weight at Month 24 (Overall Cardiovascular Study)
This change from baseline reflects the Month 24 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 24
Change From Baseline in Body Weight at Month 36 (Overall Cardiovascular Study)
This change from baseline reflects the Month 36 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 36
Change From Baseline in Body Weight at Month 48 (Overall Cardiovascular Study)
This change from baseline reflects the Month 48 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 48
Change From Baseline in Body Weight at Month 60 (Overall Cardiovascular Study)
This change from baseline reflects the Month 60 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 60
Change From Baseline in Body Weight at Month 72 (Overall Cardiovascular Study)
This change from baseline reflects the Month 72 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 72
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 18 (Overall Cardiovascular Study)
This change from baseline reflects the Week 18 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.
Time frame: Baseline and Week 18
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52 (Overall Cardiovascular Study)
This change from baseline reflects the Week 52 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.
Time frame: Baseline and Week 52
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 24 (Overall Cardiovascular Study)
This change from baseline reflects the Month 24 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.
Time frame: Baseline and Month 24
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 36 (Overall Cardiovascular Study)
This change from baseline reflects the Month 36 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.
Time frame: Baseline and Month 36
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 48 (Overall Cardiovascular Study)
This change from baseline reflects the Month 48 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.
Time frame: Baseline and Month 48
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 60 (Overall Cardiovascular Study)
This change from baseline reflects the Month 60 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.
Time frame: Baseline and Month 60
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 72 (Overall Cardiovascular Study)
This change from baseline reflects the Month 72 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.
Time frame: Baseline and Month 72
Baseline Serum Creatinine (Overall Cardiovascular Study)
Baseline reflects Week 0 serum creatinine.
Time frame: Baseline
Change From Baseline in Serum Creatinine at Week 18 (Overall Cardiovascular Study)
This change from baseline reflects the Week 18 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Week 18
Change From Baseline in Serum Creatinine at Week 52 (Overall Cardiovascular Study)
This change from baseline reflects the Week 52 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Week 52
Change From Baseline in Serum Creatinine at Month 24 (Overall Cardiovascular Study)
This change from baseline reflects the Month 24 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 24
Change From Baseline in Serum Creatinine at Month 36 (Overall Cardiovascular Study)
This change from baseline reflects the Month 36 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 36
Change From Baseline in Serum Creatinine at Month 48 (Overall Cardiovascular Study)
This change from baseline reflects the Month 48 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 48
Change From Baseline in Serum Creatinine at Month 60 (Overall Cardiovascular Study)
This change from baseline reflects the Month 60 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 60
Change From Baseline in Serum Creatinine at Month 72 (Overall Cardiovascular Study)
This change from baseline reflects the Month 72 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 72
Baseline Urinary Albumin/Creatinine Ratio (Overall Cardiovascular Study)
Baseline reflects Week 0 albumin/creatinine ratio.
Time frame: Baseline
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 18 (Overall Cardiovascular Study)
This percent change relative to baseline reflects the Week 18 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Week 18
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 52 (Overall Cardiovascular Study)
This percent change relative to baseline reflects the Week 52 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Week 52
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 24 (Overall Cardiovascular Study)
This percent change relative to baseline reflects the Month 24 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 24
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 36 (Overall Cardiovascular Study)
This percent change relative to baseline reflects the Month 36 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 36
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 48 (Overall Cardiovascular Study)
This percent change relative to baseline reflects the Month 48 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 48
Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 60 (Overall Cardiovascular Study)
This percent change relative to baseline reflects the Month 60 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.
Time frame: Baseline and Month 60
Percentage of Participants With Albuminuria Progression or Regression at Week 18 (Overall Cardiovascular Study)
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal-albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).
Time frame: Week 18
Percentage of Participants With Albuminuria Progression or Regression at Week 52 (Overall Cardiovascular Study)
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).
Time frame: Week 52
Percentage of Participants With Albuminuria Progression or Regression at Month 24 (Overall Cardiovascular Study)
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).
Time frame: Month 24
Percentage of Participants With Albuminuria Progression or Regression at Month 36 (Overall Cardiovascular Study)
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).
Time frame: Month 36
Percentage of Participants With Albuminuria Progression or Regression at Month 48 (Overall Cardiovascular Study)
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline and normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).
Time frame: Month 48
Percentage of Participants With Albuminuria Progression or Regression at Month 60 (Overall Cardiovascular Study)
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).
Time frame: Month 60
Percentage of Participants Experiencing an Adverse Event (AE) (Overall Cardiovascular Study)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to approximately 6 years
Percentage of Participants Experiencing an Adverse Event (AE) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 18 weeks
Percentage of Participants Experiencing an Adverse Event (AE) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 18 weeks
Percentage of Participants Experiencing an Adverse Event (AE) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 18 weeks
Percentage of Participants Discontinuing Study Treatment Due to An AE (Overall Cardiovascular Study)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to approximately 6 years
Percentage of Participants Discontinuing Study Treatment Due to An AE (Insulin With or Without Metformin Add-on Glycemic Sub-study)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 18 weeks
Percentage of Participants Discontinuing Study Treatment Due to An AE (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 18 weeks
Percentage of Participants Discontinuing Study Treatment Due to An AE (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 18 weeks
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in the FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Week 18
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)
This change from baseline reflects the Week 18 DBP minus the Week 0 BBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Baseline Insulin Dose for Participants Receiving Insulin at Baseline - (Insulin With or Without Metformin Add-on Glycemic Sub-study)
Baseline reflects Week 0 insulin dose.
Time frame: Baseline
Change From Baseline at Week 18 in Insulin Dose for Participants Receiving Insulin at Baseline - Including Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)
This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a decrease in insulin dose. Participants who met glycemic rescue criteria received glycemic rescue medication. "Including rescue", included data following the initiation of rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Week 18
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)
This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Week 18
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)
This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
Time frame: Baseline and Week 18
This study included participants in 34 countries at 548 study centers (Overall Cardiovascular Study).
| Milestone | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Started | 2752 | 2747 | 2747 |
| Treated | 2746 | 2747 | 2745 |
| Participants enrolled in the insulin +/- metformin glycemic sub-study | 348 | 370 | 347 |
| Participants enrolled in the sulfonylurea monotherapy glycemic sub-study | 55 | 54 | 48 |
| Participants enrolled in the metformin with sulfonylurea glycemic sub-study | 100 | 113 | 117 |
| Completed | 2422 | 2401 | 2389 |
| Not completed | 330 | 346 | 358 |
| Withdrew: Death | 228 | 233 | 247 |
| Withdrew: Lost to follow-up | 51 | 44 | 55 |
| Withdrew: Physician decision | 7 | 4 | 6 |
| Withdrew: Study site terminated by sponsor | 2 | 2 | 3 |
| Withdrew: Withdrawal by subject | 41 | 60 | 45 |
| Withdrew: Subject moved | 0 | 1 | 0 |
| Withdrew: Other | 1 | 2 | 2 |
Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke. The on-treatment approach included confirmed events that occurred between the date of first dose of study medication and the on-treatment censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or 365 days after the last dose).
| Events per 100 Person-years | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | All Ertugliflozin (Overall Cardiovascular Study) |
|---|---|---|---|---|
| Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) | 3.64 | 4.16 | 4.01 | 3.90 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.
| A1C Percentage | Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Ins+/-Met Sub-study) |
|---|---|---|---|
| Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study) | 8.45 ± 0.944 | 8.38 ± 0.985 | 8.39 ± 0.928 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| A1C Percentage | Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Ins+/-Met Sub-study) |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study) | -0.77 (-0.86 to -0.67) | -0.84 (-0.93 to -0.74) | -0.19 (-0.29 to -0.09) |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.
| A1C Percentage | Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study) |
|---|---|---|---|
| Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) | 8.27 ± 0.999 | 8.39 ± 1.019 | 8.21 ± 1.169 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| A1C Percentage | Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study) |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) | -0.91 (-1.17 to -0.65) | -0.78 (-1.06 to -0.51) | -0.56 (-0.84 to -0.27) |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects Week 0 A1C.
| A1C Percentage | Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Placebo (Metformin With Sulfonylurea Glycemic Sub-study) |
|---|---|---|---|
| Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study) | 8.39 ± 0.960 | 8.30 ± 0.963 | 8.27 ± 0.994 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| A1C Percentage | Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Placebo (Metformin With Sulfonylurea Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study) | -0.89 (-1.06 to -0.71) | -0.98 (-1.14 to -0.82) | -0.23 (-0.39 to -0.06) |
Time to the occurrence of any of the following adjudicated components of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)) or hospitalization for heart failure. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).
| Events per 100 Person-years | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | All Ertugliflozin (Overall Cardiovascular Study) |
|---|---|---|---|---|
| Time to Occurrence of Cardiovascular (CV) Death or Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study) | 2.36 | 2.33 | 2.66 | 2.34 |
Time to the occurrence of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to CV death or time to censoring (the earliest of participants' end of study date or date last known to be alive).
| Events per 100 Person-years | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | All Ertugliflozin (Overall Cardiovascular Study) |
|---|---|---|---|---|
| Time to Occurrence of Cardiovascular Death (On-study Approach) (Overall Cardiovascular Study) | 1.77 | 1.74 | 1.90 | 1.76 |
Renal composite endpoint was defined as a composite of renal death, renal dialysis/transplant, or doubling of serum creatinine from baseline. The on-study approach included events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.
| Events per 100 Person-years | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | All Ertugliflozin (Overall Cardiovascular Study) |
|---|---|---|---|---|
| Time to First Occurrence of the Renal Composite: the Composite of Renal Death, Renal Dialysis/Transplant, or Doubling of Serum Creatinine From Baseline (On-Study Approach) (Overall Cardiovascular Study) | 0.87 | 0.98 | 1.15 | 0.93 |
Time to the first occurrence of any of the following adjudicated components 4-point MACE: cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina pectoris. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.
| Events per 100 Person-years | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | All Ertugliflozin (Overall Cardiovascular Study) |
|---|---|---|---|---|
| Time to First Occurrence of MACE Plus (Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke or Hospitalization for Unstable Angina) (On-Study Approach) (Overall Cardiovascular Study) | 4.42 | 4.67 | 4.92 | 4.54 |
Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).
| Events per 100 Person-years | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | All Ertugliflozin (Overall Cardiovascular Study) |
|---|---|---|---|---|
| Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction (On-Study Approach) (Overall Cardiovascular Study) | 1.55 | 2.00 | 1.70 | 1.77 |
Time to the first occurrence of fatal and no-fatal stroke. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.
| Events per 100 Person-years | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | All Ertugliflozin (Overall Cardiovascular Study) |
|---|---|---|---|---|
| Time to First Occurrence of Fatal or Non-fatal Stroke (FNF Stroke) (On-Study Approach) (Overall Cardiovascular Study) | 0.92 | 1.04 | 0.93 | 0.98 |
Time to the first occurrence of heart failure requiring hospitalization (adjudicated). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.
| Events per 100 Person-years | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | All Ertugliflozin (Overall Cardiovascular Study) |
|---|---|---|---|---|
| Time to First Occurrence of Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study) | 0.75 | 0.72 | 1.05 | 0.73 |
Time to the occurrence of death from any cause. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or date last known to be alive. The on-study approach included events that occurred between the randomization date and the on-study censor date.
| Events per 100 Person-years | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | All Ertugliflozin (Overall Cardiovascular Study) |
|---|---|---|---|---|
| Time to Occurrence of Death From Any Cause (On-Study Approach) (Overall Cardiovascular Study) | 2.42 | 2.46 | 2.62 | 2.44 |
All events (first and recurrent) of the composite of MACE (3-point major adverse cardiovascular events: cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke) were assessed using Andersen-Gill model. The on-study approach included events that occurred between the randomization date and the on-study censor date.
| Events per 100 Person-years | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | All Ertugliflozin (Overall Cardiovascular Study) |
|---|---|---|---|---|
| Andersen-Gill Model for Total MACE (On-Study Approach) (Overall Cardiovascular Study) | 4.35 | 4.91 | 4.59 | 4.63 |
All events (first and recurrent) of the composite of CV death and HHF were assessed using an Andersen-Gill model. Person-years were calculated as the sum of time from randomization to end of follow-up. The on-study approach included events that occurred between the randomization date and the on-study censor date.
| Events per 100 Person-years | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | All Ertugliflozin (Overall Cardiovascular Study) |
|---|---|---|---|---|
| Andersen-Gill Model for All Cardiovascular Death (CV Death) or Hospitalizations for Heart Failure (HFF) (On-Study Approach) (Overall Cardiovascular Study) | 2.92 | 2.71 | 3.42 | 2.82 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| A1C Percentage | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Overall Cardiovascular Study) | -0.70 (-0.73 to -0.67) | -0.72 (-0.75 to -0.69) | -0.22 (-0.25 to -0.19) |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
| A1C Percentage | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in A1C at Week 52 (Overall Cardiovascular Study) | -0.69 (-0.73 to -0.65) | -0.67 (-0.71 to -0.63) | -0.19 (-0.23 to -0.15) |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 24 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
| A1C Percentage | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in A1C at Month 24 (Overall Cardiovascular Study) | -0.48 (-0.52 to -0.43) | -0.46 (-0.50 to -0.41) | -0.08 (-0.14 to -0.03) |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 36 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
| A1C Percentage | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in A1C at Month 36 (Overall Cardiovascular Study) | -0.42 (-0.47 to -0.37) | -0.38 (-0.43 to -0.33) | -0.04 (-0.10 to 0.01) |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 48 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
| A1C Percentage | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in A1C at Month 48 (Overall Cardiovascular Study) | -0.22 (-0.29 to -0.15) | -0.17 (-0.24 to -0.10) | 0.14 (0.07 to 0.22) |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 60 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
| A1C Percentage | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in A1C at Month 60 (Overall Cardiovascular Study) | -0.25 (-0.35 to -0.15) | -0.28 (-0.38 to -0.18) | -0.10 (-0.20 to 0.00) |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 72 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.
| A1C Percentage | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in A1C at Month 72 (Overall Cardiovascular Study) | -0.35 (-0.89 to 0.20) | -0.13 (-0.99 to 0.74) | 0.24 (-0.74 to 1.23) |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Overall Cardiovascular Study) | 28.4 | 28.2 | 15.5 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 52 (Overall Cardiovascular Study) | 28.3 | 29.0 | 17.4 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 24 (Overall Cardiovascular Study) | 23.9 | 23.8 | 16.6 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 36 (Overall Cardiovascular Study) | 23.1 | 22.7 | 16.9 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 48 (Overall Cardiovascular Study) | 24.9 | 22.7 | 18.2 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Month 60 (Overall Cardiovascular Study) | 18.6 | 20.0 | 16.5 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Week 18 (Overall Cardiovascular Study) | 9.0 | 8.8 | 4.7 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Week 52 (Overall Cardiovascular Study) | 9.4 | 10.9 | 6.1 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 24 (Overall Cardiovascular Study) | 9.2 | 8.6 | 5.8 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 36 (Overall Cardiovascular Study) | 7.9 | 8.0 | 5.8 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 48 (Overall Cardiovascular Study) | 8.1 | 9.1 | 7.5 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants With an A1C <6.5% (<48 mmol/Mol) at Month 60 (Overall Cardiovascular Study) | 5.3 | 9.5 | 6.5 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding rescue", excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study) | -32.18 (-33.76 to -30.61) | -34.64 (-36.21 to -33.08) | -17.08 (-18.69 to -15.48) |
FPG was analyzed after an overnight fast. This change from baseline reflects the Week 52 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 (Overall Cardiovascular Study) | -28.63 (-30.52 to -26.74) | -28.97 (-30.78 to -27.15) | -8.76 (-10.75 to -6.77) |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 24 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Month 24 (Overall Cardiovascular Study) | -22.09 (-24.39 to -19.80) | -24.31 (-26.76 to -21.86) | -4.39 (-6.99 to -1.78) |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 36 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Month 36 (Overall Cardiovascular Study) | -19.39 (-21.88 to -16.89) | -22.59 (-24.96 to -20.21) | -3.63 (-6.45 to -0.81) |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 48 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Month 48 (Overall Cardiovascular Study) | -15.28 (-18.66 to -11.90) | -16.16 (-19.50 to -12.83) | 3.59 (-0.22 to 7.40) |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 60 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Month 60 (Overall Cardiovascular Study) | -13.87 (-18.34 to -9.40) | -11.15 (-15.78 to -6.52) | -4.69 (-9.72 to 0.34) |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 72 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Month 72 (Overall Cardiovascular Study) | -2.46 (-31.28 to 26.36) | -84.83 (-127.31 to -42.35) | 14.56 (-23.11 to 52.22) |
Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.
| Days | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Time to the First Occurrence of a Participant Receiving Glycemic Rescue Therapy Through Week 18 (Overall Cardiovascular Study) | 59.0 (36 to 99) | 51.0 (18 to 91) | 74.0 (37 to 97) |
Participants who were not on insulin therapy at the start of study medication.
| Days | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Time to Initiation of Insulin for Participants Not on Insulin at Baseline (Overall Cardiovascular Study) | 602 (8 to 1850) | 650 (16 to 1934) | 482 (10 to 1838) |
Baseline reflects Week 0 insulin dose.
| Units/Day | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Baseline Insulin Dose for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study) | 63.82 ± 48.11 | 62.15 ± 44.46 | 65.74 ± 46.34 |
This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.
| Units/Day | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Insulin Dose at Week 18 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study) | 1.05 (0.29 to 1.82) | 0.81 (-0.10 to 1.71) | 3.71 (2.72 to 4.70) |
This change from baseline reflects the Week 52 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.
| Units/Day | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Insulin Dose at Week 52 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study) | 0.84 (-0.15 to 1.82) | -1.69 (-2.83 to -0.54) | 5.57 (4.16 to 6.98) |
This change from baseline reflects the Month 24 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.
| Units/Day | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Insulin Dose at Month 24 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study) | 0.45 (-0.72 to 1.63) | -1.58 (-2.95 to -0.21) | 6.16 (4.47 to 7.85) |
This change from baseline reflects the Month 36 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.
| Units/Day | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Insulin Dose at Month 36 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study) | 1.64 (-0.77 to 4.05) | -1.92 (-4.31 to 0.46) | 7.99 (4.65 to 11.34) |
This change from baseline reflects the Month 48 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.
| Units/Day | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Insulin Dose at Month 48 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study) | 2.96 (0.41 to 5.51) | -1.87 (-4.80 to 1.05) | 7.28 (3.66 to 10.91) |
This change from baseline reflects the Month 60 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.
| Units/Day | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Insulin Dose at Month 60 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study) | -2.47 (-9.65 to 4.72) | -1.77 (-11.95 to 8.42) | 9.42 (1.46 to 17.39) |
This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding rescue", excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study) | -2.51 (-3.00 to -2.02) | -2.75 (-3.24 to -2.26) | 0.03 (-0.48 to 0.53) |
This change from baseline reflects the Week 52 sitting SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 (Overall Cardiovascular Study) | -1.84 (-2.35 to -1.32) | -2.41 (-2.92 to -1.89) | 0.75 (0.23 to 1.26) |
This change from baseline reflects the Month 24 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 24 (Overall Cardiovascular Study) | -1.80 (-2.42 to -1.19) | -1.82 (-2.44 to -1.19) | 0.90 (0.27 to 1.53) |
This change from baseline reflects the Month 36 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 36 (Overall Cardiovascular Study) | -1.55 ± 14.56 | -1.21 ± 15.05 | 0.84 ± 14.63 |
This change from baseline reflects the Month 48 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 48 (Overall Cardiovascular Study) | -2.07 (-2.84 to -1.31) | -2.26 (-3.03 to -1.49) | 0.53 (-0.27 to 1.33) |
This change from baseline reflects the Month 60 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 60 (Overall Cardiovascular Study) | -2.18 ± 15.39 | -1.87 ± 15.01 | 0.62 ± 15.85 |
This change from baseline reflects the Month 72 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 72 (Overall Cardiovascular Study) | 1.28 (-7.63 to 10.20) | -3.46 (-10.91 to 3.99) | 2.72 (-5.95 to 11.40) |
This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding rescue", excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study) | -0.99 (-1.29 to -0.70) | -1.08 (-1.38 to -0.79) | -0.12 (-0.42 to 0.18) |
This change from baseline reflects the Week 52 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 52 (Overall Cardiovascular Study) | -0.97 (-1.28 to -0.67) | -0.95 (-1.26 to -0.65) | -0.15 (-0.45 to 0.16) |
This change from baseline reflects the Month 24 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 24 (Overall Cardiovascular Study) | -0.94 (-1.31 to -0.57) | -0.90 (-1.27 to -0.53) | -0.23 (-0.60 to 0.15) |
This change from baseline reflects the Month 36 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 36 (Overall Cardiovascular Study) | -1.27 ± 8.94 | -0.92 ± 8.89 | -0.22 ± 9.15 |
This change from baseline reflects the Month 48 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 48 (Overall Cardiovascular Study) | -1.45 (-1.93 to -0.97) | -1.42 (-1.90 to -0.94) | -0.64 (-1.14 to -0.14) |
This change from baseline reflects the Month 60 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 60 (Overall Cardiovascular Study) | -1.82 ± 8.66 | -1.43 ± 9.36 | -1.26 ± 9.38 |
This change from baseline reflects the Month 72 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 72 (Overall Cardiovascular Study) | -2.18 (-7.65 to 3.29) | 1.86 (-2.73 to 6.45) | 7.29 (1.63 to 12.94) |
This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| Kilograms | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study) | -2.03 (-2.14 to -1.92) | -2.32 (-2.43 to -2.22) | -0.40 (-0.51 to -0.30) |
This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Kilograms | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 52 (Overall Cardiovascular Study) | -2.46 (-2.61 to -2.31) | -2.84 (-2.99 to -2.69) | -0.39 (-0.54 to -0.24) |
This change from baseline reflects the Month 24 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Kilograms | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Body Weight at Month 24 (Overall Cardiovascular Study) | -2.75 (-2.95 to -2.56) | -3.17 (-3.39 to -2.95) | -0.65 (-0.85 to -0.44) |
This change from baseline reflects the Month 36 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Kilograms | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Body Weight at Month 36 (Overall Cardiovascular Study) | -3.03 (-3.24 to -2.82) | -3.41 (-3.63 to -3.20) | -0.98 (-1.20 to -0.77) |
This change from baseline reflects the Month 48 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Kilograms | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Body Weight at Month 48 (Overall Cardiovascular Study) | -3.39 (-3.69 to -3.10) | -3.83 (-4.14 to -3.51) | -1.29 (-1.59 to -1.00) |
This change from baseline reflects the Month 60 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Kilograms | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Body Weight at Month 60 (Overall Cardiovascular Study) | -3.66 (-4.11 to -3.20) | -4.58 (-5.06 to -4.11) | -1.21 (-1.63 to -0.78) |
This change from baseline reflects the Month 72 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Kilograms | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Body Weight at Month 72 (Overall Cardiovascular Study) | -4.18 (-7.83 to -0.53) | -7.37 (-12.67 to -2.07) | -0.98 (-4.13 to 2.18) |
This change from baseline reflects the Week 18 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.
| mL/min/1.73 m^2 | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 18 (Overall Cardiovascular Study) | -1.22 (-1.66 to -0.77) | -1.81 (-2.26 to -1.36) | -0.03 (-0.48 to 0.42) |
This change from baseline reflects the Week 52 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.
| mL/min/1.73 m^2 | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52 (Overall Cardiovascular Study) | -0.51 (-1.01 to -0.02) | -1.18 (-1.67 to -0.68) | -0.30 (-0.80 to 0.20) |
This change from baseline reflects the Month 24 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.
| mL/min/1.73 m^2 | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 24 (Overall Cardiovascular Study) | -1.48 (-2.07 to -0.90) | -2.35 (-2.94 to -1.76) | -2.60 (-3.20 to -2.01) |
This change from baseline reflects the Month 36 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.
| mL/min/1.73 m^2 | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 36 (Overall Cardiovascular Study) | -2.4 ± 14.0 | -2.3 ± 13.4 | -3.8 ± 14.1 |
This change from baseline reflects the Month 48 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.
| mL/min/1.73 m^2 | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 48 (Overall Cardiovascular Study) | -2.75 (-3.56 to -1.94) | -2.93 (-3.73 to -2.13) | -4.41 (-5.27 to -3.55) |
This change from baseline reflects the Month 60 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.
| mL/min/1.73 m^2 | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 60 (Overall Cardiovascular Study) | -2.4 ± 15.4 | -2.9 ± 14.1 | -6.8 ± 14.3 |
This change from baseline reflects the Month 72 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.
| mL/min/1.73 m^2 | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 72 (Overall Cardiovascular Study) | 3.7 ± 12.9 | 0.2 ± 12.2 | -1.8 ± 14.1 |
Baseline reflects Week 0 serum creatinine.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | All Ertugliflozin (Overall Cardiovascular Study) |
|---|---|---|---|---|
| Baseline Serum Creatinine (Overall Cardiovascular Study) | 0.992 ± 0.278 | 0.985 ± 0.277 | 0.991 ± 0.281 | 0.998 ± 0.278 |
This change from baseline reflects the Week 18 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Serum Creatinine at Week 18 (Overall Cardiovascular Study) | 0.022 ± 0.154 | 0.032 ± 0.148 | -0.002 ± 0.138 |
This change from baseline reflects the Week 52 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Serum Creatinine at Week 52 (Overall Cardiovascular Study) | 0.013 ± 0.166 | 0.023 ± 0.163 | 0.004 ± 0.156 |
This change from baseline reflects the Month 24 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Serum Creatinine at Month 24 (Overall Cardiovascular Study) | 0.024 ± 0.176 | 0.035 ± 0.187 | 0.034 ± 0.197 |
This change from baseline reflects the Month 36 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Serum Creatinine at Month 36 (Overall Cardiovascular Study) | 0.037 ± 0.194 | 0.035 ± 0.188 | 0.049 ± 0.194 |
This change from baseline reflects the Month 48 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Serum Creatinine at Month 48 (Overall Cardiovascular Study) | 0.032 ± 0.206 | 0.036 ± 0.196 | 0.059 ± 0.210 |
This change from baseline reflects the Month 60 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Serum Creatinine at Month 60 (Overall Cardiovascular Study) | 0.027 ± 0.202 | 0.042 ± 0.216 | 0.098 ± 0.248 |
This change from baseline reflects the Month 72 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.
| mg/dL | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Change From Baseline in Serum Creatinine at Month 72 (Overall Cardiovascular Study) | -0.034 ± 0.176 | 0.001 ± 0.120 | -0.013 ± 0.162 |
Baseline reflects Week 0 albumin/creatinine ratio.
| mg/g | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Baseline Urinary Albumin/Creatinine Ratio (Overall Cardiovascular Study) | 18.00 (6.00 to 68.00) | 19.00 (6.00 to 69.00) | 19.00 (6.00 to 66.50) |
This percent change relative to baseline reflects the Week 18 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percent Change | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 18 (Overall Cardiovascular Study) | -13.40 (-53.52 to 50.00) | -14.71 (-55.53 to 50.00) | 0.00 (-44.44 to 66.67) |
This percent change relative to baseline reflects the Week 52 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percent Change | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 52 (Overall Cardiovascular Study) | -2.53 (-50.00 to 66.67) | -6.82 (-50.00 to 66.67) | 5.41 (-40.00 to 96.34) |
This percent change relative to baseline reflects the Month 24 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percent Change | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 24 (Overall Cardiovascular Study) | -0.73 (-48.96 to 100.00) | 1.06 (-47.78 to 95.26) | 17.14 (-38.00 to 140.00) |
This percent change relative to baseline reflects the Month 36 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percent Change | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 36 (Overall Cardiovascular Study) | 13.33 (-49.34 to 120.37) | 3.33 (-49.44 to 100.00) | 27.03 (-38.46 to 177.78) |
This percent change relative to baseline reflects the Month 48 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percent Change | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 48 (Overall Cardiovascular Study) | 33.33 (-36.84 to 200.00) | 21.25 (-42.86 to 150.00) | 50.00 (-33.33 to 227.27) |
This percent change relative to baseline reflects the Month 60 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.
| Percent Change | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 60 (Overall Cardiovascular Study) | 30.99 (-40.00 to 200.00) | 20.00 (-45.83 to 150.00) | 48.53 (-28.57 to 222.41) |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal-albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants with albuminuria progression | 7.6 | 7.7 | 10.8 |
| Percentage of Participants with albuminuria regression | 14.9 | 14.7 | 10.7 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants with albuminuria progression | 9.5 | 10.2 | 12.9 |
| Percentage of Participants with albuminuria regression | 14.6 | 14.8 | 10.2 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants with albuminuria progression | 12.1 | 11.0 | 16.9 |
| Percentage of Participants with albuminuria regression | 14.3 | 13.8 | 9.9 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Participants with albuminuria progression | 14.6 | 12.5 | 18.1 |
| Participants with albuminuria regression | 13.8 | 14.3 | 11.0 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline and normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants with albuminuria progression | 19.5 | 14.9 | 21.5 |
| Percentage of Participants with albuminuria regression | 11.6 | 12.2 | 9.9 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) \<30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR\>300 (mg/g).
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants with albuminuria progression | 18.6 | 14.7 | 22.1 |
| Percentage of Participants with albuminuria regression | 11.3 | 14.8 | 10.5 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants Experiencing an Adverse Event (AE) (Overall Cardiovascular Study) | 85.8 | 84.6 | 85.6 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of Participants | Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Insulin +/- Metformin Glycemic Sub-study) |
|---|---|---|---|
| Percentage of Participants Experiencing an Adverse Event (AE) (Insulin With or Without Metformin Add-on Glycemic Sub-study) | 59.2 | 62.4 | 61.1 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of Participants | Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) |
|---|---|---|---|
| Percentage of Participants Experiencing an Adverse Event (AE) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) | 47.3 | 25.9 | 45.8 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of Participants | Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Placebo (Metformin With Sulfonylurea Glycemic Sub-study) |
|---|---|---|---|
| Percentage of Participants Experiencing an Adverse Event (AE) (Metformin With Sulfonylurea Add-on Glycemic Sub-study) | 48.0 | 54.9 | 47.0 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of Participants | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) |
|---|---|---|---|
| Percentage of Participants Discontinuing Study Treatment Due to An AE (Overall Cardiovascular Study) | 7.5 | 7.3 | 6.8 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of Participants | Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Insulin +/- Metformin Glycemic Sub-study) |
|---|---|---|---|
| Percentage of Participants Discontinuing Study Treatment Due to An AE (Insulin With or Without Metformin Add-on Glycemic Sub-study) | 2.9 | 3.8 | 3.7 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of Participants | Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) |
|---|---|---|---|
| Percentage of Participants Discontinuing Study Treatment Due to An AE (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) | 3.6 | 1.9 | 2.1 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of Participants | Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Placebo (Metformin With Sulfonylurea Glycemic Sub-study) |
|---|---|---|---|
| Percentage of Participants Discontinuing Study Treatment Due to An AE (Metformin With Sulfonylurea Add-on Glycemic Sub-study) | 0 | 2.7 | 1.7 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in the FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| mg/dL | Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Insulin +/- Metformin Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study) | -26.98 (-32.80 to -21.17) | -33.15 (-38.81 to -27.48) | -7.74 (-13.67 to -1.81) |
This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| Kilograms | Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Insulin +/- Metformin Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study) | -1.87 (-2.22 to -1.52) | -2.13 (-2.47 to -1.79) | -0.25 (-0.60 to 0.11) |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| Percentage of Participants | Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Insulin +/- Metformin Glycemic Sub-study) |
|---|---|---|---|
| Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study) | 20.7 | 21.1 | 10.7 |
This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| mmHg | Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Insulin +/- Metformin Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study) | -2.67 (-4.17 to -1.18) | -2.12 (-3.57 to -0.67) | 0.20 (-1.33 to 1.74) |
This change from baseline reflects the Week 18 DBP minus the Week 0 BBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| mmHg | Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Insulin +/- Metformin Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study) | -0.86 (-1.72 to -0.00) | -0.64 (-1.47 to 0.20) | -0.26 (-1.14 to 0.62) |
Baseline reflects Week 0 insulin dose.
| Unit/day | Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Insulin +/- Metformin Glycemic Sub-study) |
|---|---|---|---|
| Baseline Insulin Dose for Participants Receiving Insulin at Baseline - (Insulin With or Without Metformin Add-on Glycemic Sub-study) | 70.76 ± 44.15 | 67.29 ± 41.23 | 73.20 ± 49.58 |
This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a decrease in insulin dose. Participants who met glycemic rescue criteria received glycemic rescue medication. "Including rescue", included data following the initiation of rescue therapy.
| Unit/day | Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Insulin +/- Metformin Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline at Week 18 in Insulin Dose for Participants Receiving Insulin at Baseline - Including Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study) | -0.71 ± 10.14 | -2.14 ± 10.23 | -0.29 ± 11.49 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| mg/dL | Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) | -28.28 (-39.44 to -17.12) | -26.97 (-38.51 to -15.44) | -14.76 (-26.43 to -3.08) |
This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| Kilograms | Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) | -1.75 (-2.61 to -0.89) | -1.20 (-2.09 to -0.31) | -0.68 (-1.60 to 0.25) |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| Percentage of Participants | Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) |
|---|---|---|---|
| Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) | 32.7 | 27.8 | 25.0 |
This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| mmHg | Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) | -0.72 (-4.06 to 2.63) | -0.80 (-4.23 to 2.63) | -3.53 (-7.03 to -0.02) |
This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| mmHg | Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) | -1.18 (-3.24 to 0.88) | -0.93 (-3.05 to 1.18) | -2.91 (-5.06 to -0.76) |
FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| mg/dL | Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Placebo (Metformin With Sulfonylurea Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study) | -35.28 (-43.05 to -27.50) | -36.18 (-43.36 to -28.99) | -4.81 (-12.10 to 2.49) |
This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| Kilograms | Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Placebo (Metformin With Sulfonylurea Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study) | -2.04 (-2.58 to -1.50) | -2.41 (-2.91 to -1.91) | -0.47 (-0.97 to 0.03) |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| Percentage of Participants | Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Placebo (Metformin With Sulfonylurea Glycemic Sub-study) |
|---|---|---|---|
| Percentage of Participants With an A1C <7% (<53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study) | 37.0 | 32.7 | 12.8 |
This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| mmHg | Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Placebo (Metformin With Sulfonylurea Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study) | -2.26 (-4.78 to 0.25) | -1.54 (-3.85 to 0.77) | -0.70 (-3.04 to 1.64) |
This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. "Excluding Rescue" excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.
| mmHg | Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Placebo (Metformin With Sulfonylurea Glycemic Sub-study) |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study) | -0.30 (-1.80 to 1.21) | -0.92 (-2.30 to 0.46) | -0.24 (-1.64 to 1.15) |
Collected over Overall Cardiovascular study - Up to approximately 6 years 3 Glycemic Sub-studies - Up to 18 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 228/2,746 (8.3%) | 958/2,746 (34.9%) | 1,405/2,746 (51.2%) |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 233/2,747 (8.5%) | 937/2,747 (34.1%) | 1,389/2,747 (50.6%) |
| Placebo (Overall Cardiovascular Study) | 247/2,745 (9%) | 990/2,745 (36.1%) | 1,395/2,745 (50.8%) |
| Ertugliflozin 5 mg (Insulin +/- Metformin Sub-study) | 4/348 (1.1%) | 33/348 (9.5%) | 127/348 (36.5%) |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | 6/370 (1.6%) | 27/370 (7.3%) | 144/370 (38.9%) |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | 1/347 (0.3%) | 37/347 (10.7%) | 135/347 (38.9%) |
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | 0/55 (0%) | 4/55 (7.3%) | 10/55 (18.2%) |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | 1/54 (1.9%) | 1/54 (1.9%) | 4/54 (7.4%) |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study) | 0/48 (0%) | 2/48 (4.2%) | 9/48 (18.8%) |
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 0/100 (0%) | 7/100 (7%) | 24/100 (24%) |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 1/113 (0.9%) | 8/113 (7.1%) | 32/113 (28.3%) |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | 0/117 (0%) | 6/117 (5.1%) | 26/117 (22.2%) |
| Event | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | Ertugliflozin 5 mg (Insulin +/- Metformin Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study) | Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Placebo (Metformin With Sulfonylurea Glycemic Sub-study) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Angina unstableCardiac disorders | 74/2746 | 71/2747 | 89/2745 | 3/348 | 1/370 | 1/347 | 0/55 | 0/54 | 1/48 | 0/100 | 2/113 | 0/117 |
| Acute myocardial infarctionCardiac disorders | 52/2746 | 76/2747 | 73/2745 | 3/348 | 1/370 | 1/347 | 0/55 | 0/54 | 0/48 | 1/100 | 1/113 | 0/117 |
| Ischaemic strokeNervous system disorders | 29/2746 | 40/2747 | 41/2745 | 1/348 | 0/370 | 1/347 | 0/55 | 1/54 | 1/48 | 0/100 | 0/113 | 0/117 |
| PneumoniaInfections and infestations | 51/2746 | 46/2747 | 45/2745 | 1/348 | 0/370 | 0/347 | 0/55 | 0/54 | 0/48 | 0/100 | 0/113 | 0/117 |
| Cardiac failure acuteCardiac disorders | 7/2746 | 7/2747 | 8/2745 | 0/348 | 0/370 | 0/347 | 0/55 | 1/54 | 0/48 | 0/100 | 0/113 | 0/117 |
| Myocardial infarctionCardiac disorders | 39/2746 | 49/2747 | 37/2745 | 1/348 | 0/370 | 2/347 | 0/55 | 1/54 | 0/48 | 1/100 | 0/113 | 1/117 |
| Acute coronary syndromeCardiac disorders | 9/2746 | 6/2747 | 8/2745 | 0/348 | 0/370 | 0/347 | 1/55 | 0/54 | 0/48 | 0/100 | 0/113 | 0/117 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/2746 | 1/2747 | 0/2745 | 0/348 | 0/370 | 0/347 | 1/55 | 0/54 | 0/48 | 0/100 | 0/113 | 0/117 |
| DizzinessNervous system disorders | 2/2746 | 2/2747 | 4/2745 | 0/348 | 0/370 | 0/347 | 1/55 | 0/54 | 0/48 | 0/100 | 0/113 | 0/117 |
| Extremity necrosisVascular disorders | 2/2746 | 6/2747 | 4/2745 | 0/348 | 0/370 | 0/347 | 1/55 | 0/54 | 0/48 | 0/100 | 0/113 | 0/117 |
| Event | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | Ertugliflozin 5 mg (Insulin +/- Metformin Sub-study) | Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | Placebo (Insulin +/- Metformin Glycemic Sub-study) | Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study) | Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | Placebo (Metformin With Sulfonylurea Glycemic Sub-study) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 883/2746 | 854/2747 | 884/2745 | 101/348 | 112/370 | 109/347 | 3/55 | 3/54 | 0/48 | 13/100 | 19/113 | 14/117 |
| Urinary tract infectionInfections and infestations | 256/2746 | 262/2747 | 211/2745 | 8/348 | 9/370 | 7/347 | 1/55 | 1/54 | 0/48 | 1/100 | 4/113 | 3/117 |
| NasopharyngitisInfections and infestations | 178/2746 | 204/2747 | 186/2745 | 4/348 | 13/370 | 11/347 | 1/55 | 0/54 | 2/48 | 2/100 | 5/113 | 3/117 |
| Upper respiratory tract infectionInfections and infestations | 197/2746 | 177/2747 | 203/2745 | 8/348 | 10/370 | 9/347 | 0/55 | 0/54 | 0/48 | 3/100 | 2/113 | 4/117 |
| HyperglycaemiaMetabolism and nutrition disorders | 106/2746 | 96/2747 | 178/2745 | 5/348 | 9/370 | 6/347 | 0/55 | 0/54 | 2/48 | 3/100 | 2/113 | 1/117 |
| HypertensionVascular disorders | 133/2746 | 148/2747 | 168/2745 | 5/348 | 4/370 | 2/347 | 2/55 | 0/54 | 2/48 | 4/100 | 2/113 | 3/117 |
| Back painMusculoskeletal and connective tissue disorders | 133/2746 | 138/2747 | 143/2745 | 2/348 | 2/370 | 2/347 | 2/55 | 0/54 | 2/48 | 1/100 | 1/113 | 2/117 |
| DizzinessNervous system disorders | 139/2746 | 141/2747 | 89/2745 | 8/348 | 9/370 | 4/347 | 1/55 | 0/54 | 0/48 | 2/100 | 4/113 | 1/117 |
| DiarrhoeaGastrointestinal disorders | 132/2746 | 138/2747 | 126/2745 | 7/348 | 9/370 | 8/347 | 0/55 | 0/54 | 1/48 | 2/100 | 3/113 | 0/117 |
The analysis population is all randomized participants.
| Age, Continuous(Years) | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | Total |
|---|---|---|---|---|
| Mean | 64.3 ± 8.2 | 64.4 ± 8.0 | 64.4 ± 8.0 | 64.4 ± 8.1 |
| Sex: Female, Male(Participants) | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | Total |
|---|---|---|---|---|
| Female | 801 | 832 | 844 | 2477 |
| Male | 1951 | 1915 | 1903 | 5769 |
| Ethnicity (NIH/OMB)(Participants) | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 353 | 347 | 343 | 1043 |
| Not Hispanic or Latino | 2390 | 2392 | 2399 | 7181 |
| Unknown or Not Reported | 9 | 8 | 5 | 22 |
| Race (NIH/OMB)(Participants) | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 13 | 8 | 17 | 38 |
| Asian | 187 | 149 | 162 | 498 |
| Native Hawaiian or Other Pacific Islander | 4 | 10 | 15 | 29 |
| Black or African American | 91 | 75 | 69 | 235 |
| White | 2390 | 2436 | 2414 | 7240 |
| More than one race | 67 | 69 | 70 | 206 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Fasting Plasma Glucose (FPG)(mg/dL) | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | Total |
|---|---|---|---|---|
| Mean | 176.1 ± 52.5 | 174.8 ± 51.6 | 173.6 ± 49.4 | 174.8 ± 51.2 |
| Sitting Systolic Blood Pressure (SBP)(mmHg) | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | Total |
|---|---|---|---|---|
| Mean | 133.7 ± 13.7 | 133.2 ± 13.8 | 133.1 ± 13.9 | 133.3 ± 13.8 |
| Sitting Diastolic Blood Pressure (DBP)(mmHg) | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | Total |
|---|---|---|---|---|
| Mean | 76.8 ± 8.5 | 76.7 ± 8.2 | 76.4 ± 8.7 | 76.6 ± 8.5 |
| Body Weight(Kilograms) | Ertugliflozin 5 mg (Overall Cardiovascular Study) | Ertugliflozin 15 mg (Overall Cardiovascular Study) | Placebo (Overall Cardiovascular Study) | Total |
|---|---|---|---|---|
| Mean | 91.9 ± 18.4 | 91.6 ± 18.6 | 91.9 ± 18.3 | 91.8 ± 18.4 |
2 further baseline measures are reported on the registry.
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2013 to primary completion in Dec 2019, 73 months.
Results were first posted in Feb 2021, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 73 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin